Brief: Ascentage Pharma Group International Says MDM2-P53 Inhibitor, APG-115 Got An Orphan Drug Designation By U.S. FDA
21/07/2021 13:25
July 21 (Reuters) - Ascentage Pharma Group International
6855.HK :
* MDM2-P53 INHIBITOR, APG-115 GOT AN ORPHAN DRUG DESIGNATION
BY
U.S. FDA
Source text for Eikon: urn:newsml:reuters.com:*:nHKS4vXDsL
Further company coverage: 6855.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up